Tech Company Financing Transactions
Stelexis Therapeutics Funding Round
On 1/9/2019, Stelexis Therapeutics secured $43 million in Series A funding from Deerfield Capital.
Transaction Overview
Company Name
Announced On
1/9/2019
Transaction Type
Venture Equity
Amount
$43,000,000
Round
Series A
Investors
Deerfield Capital (Robert Jackson)
Proceeds Purpose
With these funds we are now positioned to execute on our potential to transform patients' lives.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
780 3rd Ave.
New York, NY 10017
USA
New York, NY 10017
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Stelexis' mission is to become the leading cancer therapeutics company, through the discovery and development of novel drugs, utilizing its proprietary platform to selectively target pre-cancerous stem cells. The company will initially focus on therapeutics for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Patrick Doyle
Chief Scientific Officer
Keren Paz
Browse more venture capital transactions:
Prev: 1/9/2019: LendingFront venture capital transaction
Next: 1/9/2019: GreenLight Biosciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs